Novartis: 2 Significant Pipeline Setbacks Can Be Absorbed

Novartis shares plunged after late-stage failures of pelacarsen and del-desiran weakened its long-term growth pipeline. The company reaffirmed 2025-2030 revenue growth guidance of 5-6% CAGR, while Rhapsido's successful phase 3 data in relapsing multiple sclerosis provides a partial offset with potential annual peak sales exceeding $3 billion. The pipeline setbacks nevertheless raise execution risk around Novartis' longer-term growth outlook.

Analysis

The key valuation issue is not the near-term revenue hole but the reduction in NVS's late-decade optionality: two late-stage setbacks increase the probability that management must rely on business-development spending to protect its 5-6% growth algorithm. That would pressure capital returns and potentially lift the cost of sustaining growth, warranting a lower terminal multiple even if near-term guidance remains intact. Watch for 2028-2030 consensus sales and EPS cuts over the next one to three months; those revisions, rather than the initial clinical-news move, should determine whether the de-rating persists.

Rhapsido can offset some pipeline value, but a $3B peak-sales outcome requires rapid displacement in a crowded RMS market. Its commercial upside depends on efficacy, safety, monitoring burden and payer positioning versus established high-efficacy therapies from Roche (RHHBY), Biogen (BIIB), Bristol Myers (BMY) and Sanofi (SNY); positive trial data alone does not establish durable share capture. The six-to-eighteen-month catalyst path is regulatory labeling and launch guidance, where any boxed-warning, infection signal, or conservative peak-sales framing would expose the gap between pipeline optimism and executable revenue.

The contrarian read is that the selloff may over-attribute value to assets that had not yet been fully risk-adjusted in sell-side models. However, the more important negative read-through is to Ionis (IONS) if pelacarsen economics included material milestones and downstream royalties; this is a contractual-exposure question rather than an automatic sector short. For Lp(a) competitors such as Amgen (AMGN) and Eli Lilly (LLY), the result is only positive if it reflects molecule-specific limitations; evidence of target-class efficacy or safety limitations would reverse that interpretation.

Key Decisions for Investors

• Maintain a neutral-to-underweight NVS stance for the next 1-3 months; do not buy the initial decline until consensus 2030 sales estimates have been reset and management quantifies replacement pipeline or business-development needs. Thesis is falsified by unchanged long-range consensus estimates plus credible, funded replacement assets.
• Use NVS as a relative short versus RHHBY rather than a broad pharma short if the valuation gap remains narrow: Roche retains established RMS franchise economics while NVS must prove Rhapsido can displace incumbents. Reassess following regulatory labeling or if Rhapsido demonstrates clearly differentiated safety and efficacy.
• Place IONS on an alert list rather than initiate a position: verify pelacarsen milestone, royalty and remaining-development-rights exposure in filings. A material reduction in expected partner payments would create a second-order earnings risk not necessarily reflected in the initial NVS move.
• Avoid treating AMGN or LLY as automatic beneficiaries until detailed pelacarsen failure data are available. If the issue is delivery, tolerability, or target engagement rather than trial design, reduce any Lp(a)-competition long exposure; if molecule-specific, the competitive field narrows and their programs gain strategic value.